Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company imports and sells medicines.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 1,464 | 1,130 | 927 | 242 | 1,928 | 2,056 | 1,304 | -1.9% |
| Net Cash used in Investing Activities | 1,277 | 0 | 0 | 87 | 0 | 89 | 22 | -49.3% |
| Free Cash Flow (OCF − Capex proxy) | 187 | 1,130 | 927 | 156 | 1,928 | 1,967 | 1,283 | +37.9% |
| Net Cash from Financing Activities | 255 | 1,109 | 1,004 | 210 | 2,216 | 1,912 | 1,291 | +31.0% |
| Net Change in Cash (before FX) | 69 | 21 | 77 | 54 | 288 | 55 | 8 | -29.7% |
| Effect of FX on Cash | 0 | 0 | 0 | 0 | 3 | 0 | 3 | nmf |
| Net Change in Cash (incl. FX) | 69 | 21 | 77 | 54 | 285 | 55 | 11 | -25.8% |
| Cash at Beginning of Year | 529 | 461 | 482 | 405 | 351 | 66 | 121 | -21.8% |
| Cash at End of Year | 461 | 482 | 405 | 351 | 66 | 121 | 109 | -21.3% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →